We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled Mannitol and Ciliary Beat Frequency in COPD Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00446121
Recruitment Status : Unknown
Verified March 2007 by Imperial College London.
Recruitment status was:  Recruiting
First Posted : March 12, 2007
Last Update Posted : March 12, 2007
Sponsor:
Information provided by:

Study Description
Brief Summary:
The main purpose of the study is to evaluate the effect of mannitol on the cilia's beat frequency (ciliary beat frequency) in COPD patients.

Condition or disease
Chronic Obstructive Pulmonary Disease

Study Design

Study Type : Observational
Observational Model: Defined Population
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
Official Title: The Effect of Inhaled Mannitol on Ciliary Beat Frequency in COPD Patients

Resource links provided by the National Library of Medicine

Drug Information available for: Mannitol
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   38 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COPD
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00446121


Contacts
Contact: Sergei Kharitonov, MD PhD +44 02073518051 s.kharitonov@imperial.ac.uk
Contact: Lars Pedersen, MD +44 02073518051 l.pedersen@imperial.ac.uk

Locations
United Kingdom
Airway Disease Section, Asthma Lab, Imperial College London, Royal Brompton Hospital Recruiting
London, United Kingdom, SW3 6LY
Contact: Sergei Kharitonov, MD PhD    +44 02073518051    s.kharitonov@imperial.ac.uk   
Contact: Lars Pedersen, MD    +44 02073518051    l.pedersen@imperial.ac.uk   
Principal Investigator: Sergei Kharitonov, MD PhD         
Sub-Investigator: Lars Pedersen, MD         
Sub-Investigator: Peter J Barnes, MA DM DSc FRCP         
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Sergei Kharitonov, MD PhD Imperial College London
More Information

ClinicalTrials.gov Identifier: NCT00446121     History of Changes
Other Study ID Numbers: 06/Q0410/55
First Posted: March 12, 2007    Key Record Dates
Last Update Posted: March 12, 2007
Last Verified: March 2007

Keywords provided by Imperial College London:
COPD

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Mannitol
Diuretics, Osmotic
Diuretics
Natriuretic Agents
Physiological Effects of Drugs